ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Amlodipine

Also written as “amlodipine”, “Amlodipine 5 mg” and “Amlodipine 10 mg”.

Its studies are mostly in Hypertension · Essential Hypertension · Hyperlipidemias · Kidney Diseases · Hypercholesterolemia, led by 35 companies.

Drug pageAmlodipine: every studyMany companies study it; this page follows only the 170 they lead. All 284 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 25, 2005170 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis570 open or runningphase 4since Aug 25, 2005Aug 25, 2005none ahead
Boehringer Ingelheimits history only220 open or runningphase 4since Oct 14, 2005Oct 14, 2005none ahead
Viatrisits history only130 open or runningphase 4since Aug 31, 2005Aug 31, 2005none ahead
Hanmi Pharmaceuticalits history only110 open or runningphase 3since Jul 14, 2009Jul 14, 2009none ahead
Dr. Reddy's Laboratoriesits history only80 open or runningphase 1since May 26, 2010May 26, 2010none ahead
HK inno.Nits history only50 open or runningphase 3since Feb 16, 2015Feb 10, 2014none ahead
Handokits history only40 open or runningphase 3since Jul 24, 2022Jul 21, 2020none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Feb 9, 2009Feb 9, 2009none ahead
Yuhanits history only41 open or runningphase 4since Sep 4, 2023May 29, 2014none ahead
Chong Kun Dang Pharmaceuticalits history only30 open or runningphase 3since Jan 8, 2016Feb 14, 2014none ahead

Also a collaborator on its studies: CSPC Pharmaceutical Group and Integrium.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 42 studies since Aug 25, 2005.

  1. Nov 24, 2008Phase 3 study in HypertensionNCT00797862 · 1,254 enrolled · Canada, Costa Rica, France and more
  2. Feb 10, 2009Phase 3 study in HypertensionNCT00841672 · 485 enrolled · Germany, Philippines, Romania and more
  3. Feb 26, 2009Phase 4 study in HypertensionNCT00853957 · 443 enrolled · United States
  4. Apr 28, 2009Phase 4 study in HypertensionNCT00902304 · 2,337 enrolled · United States, Australia
  5. Jul 1, 2009Phase 4 study in Isolated Systolic HypertensionNCT00931710 · 488 enrolled · United States
  6. Oct 15, 2009Phase 3 study in Essential HypertensionNCT01001572 · 932 enrolled
  7. Feb 6, 20102 phase 4 studies in HypertensionNCT01070043, NCT01070030
  8. Mar 3, 2010Phase 2 study in HypertensionNCT01080768 · 31 enrolled · Netherlands
  9. Apr 27, 2010Phase 3 study in Essential HypertensionNCT01113047 · 347 enrolled · Germany
  10. Jul 20, 2010Phase 4 study in HypertensionNCT01167153 · 564 enrolled · China
  11. Oct 29, 2010Phase 3 study in Essential HypertensionNCT01237223 · 1,342 enrolled · Japan
  12. Nov 15, 2010Phase 4 study in Essential HypertensionNCT01241487 · 150 enrolled · Egypt
  13. Dec 10, 2010Phase 3 study in Cardiovascular EventsNCT01259297 · 2,336 enrolled · United States, Argentina, Brazil and more
  14. Feb 12, 2014Phase 4 study in Essential HypertensionNCT02062645 · 115 enrolled · Turkey

TargetBeta

“Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker; Voltage-gated L-type calcium channel blocker”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
PregabalinruleViatrisphase 4149
GabapentinruleViatrisphase 449
DronedaroneruleSanofiphase 418
NifedipineruleBayerphase 418

Studies

All 57 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02062645Essential Hypertension · Turkey4CompletedSep 2015115
NCT01259297Cardiovascular Events · United States, Argentina, Brazil and more3TerminatedNov 20122,336
NCT01241487Essential Hypertension · Egypt4CompletedJan 2011150
NCT01237223Essential Hypertension · Japan3CompletedMay 20111,342
NCT01167153Hypertension · China4CompletedApr 2011564
NCT01113047Essential Hypertension · Germany3CompletedOct 2010347
NCT01080768Hypertension · Netherlands2TerminatedNov 201031
NCT01070030Hypertension · Thailand4CompletedOct 2010230
NCT01070043Hypertension · Taiwan4CompletedSep 201060
NCT01001572Essential Hypertension3CompletedMay 2010932
NCT00931710Isolated Systolic Hypertension · United States4CompletedJan 2010488
NCT00902304Hypertension · United States, Australia4CompletedJul 20112,337
NCT00853957Hypertension · United States4CompletedAug 2009443
NCT00841672Hypertension · Germany, Philippines, Romania and more3CompletedSep 2009485
NCT00797862Hypertension · Canada, Costa Rica, France and more3CompletedNov 20101,254
NCT00778921Hypertension · Argentina, Germany, Norway and more3CompletedJun 2009847
NCT00777946Hypertension · Estonia, France, Iceland and more3CompletedMay 2009818
NCT00765674Hypertension · United States, Australia, Canada and more3CompletedAug 20091,191
NCT00739973Hypertension · United States, Argentina, Australia and more3CompletedMay 20092,694
NCT00667719Essential Hypertension · United States, Belgium, Egypt and more3CompletedOct 5, 2009564
NCT00666536Hypertension · United States4CompletedJan 2009728
NCT00687973Hypertension · France4CompletedJan 2009393
NCT00700271Hypertension · France, Tunisia4CompletedAug 2008478
NCT00548067Hypertension · India3Completed111
NCT00523744Hypertension · Germany3CompletedDec 2007257
NCT00523549Hypertension · United States4CompletedJan 2008229
NCT00446563Hypertension · Germany3CompletedMar 201090
NCT00446524Hypertension · Japan3CompletedOct 2008403
NCT00437645Essential Hypertension · Argentina, Chile, Ecuador and more3CompletedNov 20071,183
NCT00426478Hypertension · Taiwan4Completed80
NCT00425997Hypertension · United States4CompletedOct 2007480
NCT00425373Essential Hypertension · Japan3CompletedMar 20081,474
NCT00413413Hypertension · China3CompletedNov 20071,134
NCT00413049Hypertension · China3CompletedNov 2007698
NCT00409851Hypertension · United States, Germany3CompletedMar 20051,293
NCT00409760Hypertension · Germany3CompletedFeb 20041,930
NCT00409643Hypertension · United States, Germany3CompletedJul 20041,259
NCT00402103Hypertension · United States, Belgium, Denmark and more3CompletedApr 2008556
NCT00400777Hypertension · Brazil4CompletedNov 2007460
NCT00392262Hypertension · Germany, Switzerland3CompletedFeb 2007224
NCT00367978Hypertension · United States4CompletedSep 2003275
NCT00367939Hypertension · Germany3CompletedJul 2006132
NCT00353912Hypertension · United States3CompletedApr 2007571
NCT00350168Hypertension · United States3CompletedApr 2007647
NCT00327587Hypertension · United States3CompletedAug 20072,279
NCT00327145Hypertension · Switzerland3CompletedJan 2007894
NCT00351130Hypertension · Germany, Switzerland4CompletedMar 200779
NCT00304226Hypertension · Germany, Switzerland4CompletedJan 20071,288
NCT00171535Hypertension · United States3CompletedApr 2005130
NCT00171366Hypertension · United States3CompletedJul 20051,422
NCT00171054Hypertension · Switzerland4CompletedOct 2007125
NCT00171002Hypertension · Germany, Switzerland3CompletedJun 2005936
NCT00170976Hypertension · Germany, Switzerland3CompletedJun 2005403
NCT00170963Hypertension · Germany, Switzerland3CompletedJun 20051,018
NCT00170950Hypertension · United States, Denmark, Finland and more3TerminatedJan 200811,506
NCT00139555Hypertension · United States4CompletedNov 2006125
NCT00136773Albuminuria4CompletedOct 2005332

How it is read

Names in the registry

  • “Amlodipine”, 44 entries
  • “amlodipine”, 14 entries
  • “Amlodipine 5 mg”, 9 entries
  • “Amlodipine 10 mg”, 6 entries
  • “valsartan + amlodipine”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.